Scientific paper 2-Dimensional Quantitative Structure-Activity Relationship Modeling Study of Glycine/ N-methyl-D-aspartate Antagonist Inhibition: Genetic Function Approximation Vis-à-vis Multiple Linear Regression Methods Nitin S. Sapre1*, Nilanjana Pancholi1, Swagata Gupta2 and Arun Sikarwar3 1 Department of Applied Chemistry, Shri GS Institute of Technology and Sciences, Indore, MP, India, Pin 452001. 2 Department of Chemistry, Govt. P.G. College, MHOW, MP, India. 3 Department of Chemistry, Holkar Science College, MP, India. * Corresponding author: E-mail: sukusap@yahoo.com Received: 12-04-2007 Abstract A comparative study of genetic function approximation (GFA) and multiple linear regression analysis(MLR) techniques for understanding 2D quantitative structure-activity relationship (2D-QSAR) on N-methyl-D-aspartate (NMDA) inhibitors was conducted using distance and connectivity based topological indices (Wiener, Balaban and Randic Indices). Models generated were used to predict the inhibitory activity for a set of test compounds. The results indicated that the GFA method proved to be superior of the two in developing 2D QSAR model in all the cases (Uni- as well as multi-variate). Individual topological indices have also been studied to understand their correlation potential. In all the cases (Wiener, Balaban and Randic), the results gave a high value of correlation (R2 > 0.80, Q2 > 0.79) for the GFA method while the MLR method yielded poor correlation (R2 < 0.60 and Q2 < 0.55). Among the three indices, Randic connectivity index proved to be the best in describing the 2D-QSAR for this series of NMDA inhibitors (R2 = 0.893, Q2 = 0.880, F-ratio = 216.393) Keywords: QSAR, NMDA, GFA, MLR, Wiener index, Randic index, Balaban index 1. Introduction Distance and connectivity based topological indices, their correlation potential and applications in understanding the quantitative structure-activity relationship (QSAR) has been a matter of great interest to the chemistry community for the past decade or so.1-7 The beauty of these indices is their easy understandability and applicability. Actual applications of topological indices do not limit to small-sized molecules only, but have crossed the traditional frontiers and have been successfully applied to bigger molecules, such as proteins and RNAs.8,9 Some recent works studied the similarities and relationships between different topological indices and justified in principle, the selection of a group of arbitrary topological indices (e.g. W, J, %, or M1) for evaluation of a model without using all the known indices.10 Use of topological indices has been well illustrated in the literature.11-18 Use of topological indices in understanding the Glycine/NMDA receptor inhibition has not been reported so far. It has been observed that N-methyl-D-aspartate (NMDA) receptor play a key role in several abnormal brain processes such as Alzheimer's disease, Huntington's disease, epilepsy, and cerebral ischemia.19-23 The NMDA receptor requires the occupation of two distinct recognition sites by glutamate and glycine, the latter at the so-called Gly-NMDA site for activation.24,25 Glycine acts as an endogenous coagonist at its site.26,27 Most of the selective receptor agonists available are based on NMDA, the diagnostic ligand for these receptors. NMDA itself is an analogue of aspartate (can also act as a weak agonist at most glutamate receptors). Although this compound acts selectively at NMDA receptors, it cannot discriminate between receptor subtypes. A variety of potent and selective agonists to NMDA receptor are present. To mention a few; trans-ACBD,28 cis-ACPD,29 D-aspartic acid,29 L-aspartic acid ( endogenous NMDA agonist ),29 CCMQ,30 D and L-glutamic acid (D is less active than the L isomer),29,31 and homoquinolinic acid.30 Auerbach et al.32 has suggested that the structural studies indicate that the binding of agonists causes a conformational change in the S1-S2 binding site domains of the protein. However, the details of the molecular events that constitute the global conformational change in the protein ("gating") remain unknown. Use of binding free energy/hydration free energy as an additional descriptor in performing SAR studies can be of immense importance in unraveling the chemistry of binding of molecules and can perhaps serve as a tool for distinguishing agonists from antagonists.33-37 A reliable method of evaluating these free energies is by using Langevin dipoles.38,39 Some of the potent and competitive NMDA antagonists widely used are DL-AP5,40 D-AP5,40 DL-AP7(First generation phosphono NMDA antagonist),41 CGP 37849,42 SDZ 220-581.43 With the discovery of the stimulatory action of glycine on the NMDA receptor, it was found that these effects of glycine were blocked by kynurenic acid KA, a weak and nonselective NMDA antagonist.44,45 KA has a very weak affinity for the Gly-NM-DA site and is not selective, having a similar potency as that of an antagonist at both NMDA and non-NMDA receptors, kainate and AMPA. KA on chemical modifications, however, has produced compounds with very high affinity.46-50 Recently, a structure-activity study of 5- and 7-substituted KA derivatives was presented.47 The biological property analyzed was the functional antagonist potency assessed by the determination of the apparent dissociation constants for the antagonism of the depolarization induced by NMDA. The remarkably important properties of these compounds require more research on their structure-activity relationships (SAR).This article reports results of comparative 2D-QSAR study using two statistical techniques namely MLR and GFA. Connectivity and distance based graph theoretical indices are used to perform correlations with the inhibitory activity of NMDA derivatives. 2. Molecular Modeling Methods A series of 55 NMDA inhibitors51 with their inhibition data is taken to perform 2D-QSAR studies. In an attempt to have a precise and detailed understanding of QSAR, graph theoretical descriptors namely Wiener (W), Randic (1%R) and Balaban (J) were used to describe 2D QSAR for the aforementioned series of NMDA inhibitors. In developing QSAR, logIC50 value was used as the dependent variable. MLR and GFA methods are used for performing correlation analysis. Transformation of the chemical structures of these NMDA inhibitors into a mathematical graph makes it possible to express their chemical structures by a single numerical index. As it is well known, such a numerical index characterizing a molecule (or a corresponding molecular graph) is called a topological index.12-15 Therefore; a topological index expresses topological information for a given chemical structure. The advantage of the topologi-cal indices is that they may be directly used as single molecular descriptors in QSAR as well as QSPR studies. These relationships are mathematical models that enable the prediction of activity or properties from their structural parameters. The structures for the compounds were generated and energy minimization procedures were carried out using Sybyl 6.952 while Gasteiger Marsili charges were assigned using Tripos force field. Cerius2®53 was used to calculate the topological descriptors as well as to perform Multiple Linear Regression (MLR) and Genetic Function Approximation (GFA) analysis for the 2D QSAR studies on Silicon Graphics® Octane2 duel processor workstation. 2. 1. 2D-QSAR: Topological Indices Used All the three topological indices, namely Wiener index (W), Randic (1%R) and Balaban (J) are well presented in the literature.14,15 Therefore, they will be described here rather briefly. 2. 1. 1. The Wiener Index (W) In 1947 Wiener16 developed a number: Wiener number (W) that could characterize molecular branching. Wiener himself correlated a number of properties with W including boiling points and various thermodynamic parameters. Stiel and Thodos54 used W to predict critical constant. Rouvray and Crafford55 correlated W with density, viscosity and surface tension. Popazova and Bon-chev56 correlated W with chromatographic retention times. The index has also been used in the prediction of antibacterial activity.57 The Wiener index, W=W (G), of a graph is defined as the half the sum of the elements of the distance matrix where (dj is the ijth element of the distance matrix D, which denotes the shortest graph theoretical distance between vertices i and j in G. All the graphs are hydrogen suppressed. 2. 1. 2. The Randic Connectivity Index 0%R) In 1975 Randic proposed a topological index,17 that has most wide utility in both QSPR and QSAR studies. It makes use of vertices present in the chemical graph and is therefore sensitive to the shape of the chemical cluster. This is also known as molecular connectivity index. Molecular connectivity has been extensively employed in the QSPR and QSAR studies, by Keir and Hall. 1256 The connectivity index % = %(G), of G is defined17 as (2) where 5 and 5 are the valences of the vertices i and j, i j equal to the number of bonds connected to the atoms i and j in G, representing the graph of a compound. 2. 1. 3. The Balaban Index (J) The topological index of Balaban is based on the distance matrix of the graph G and is known as averaged distance sum connectivity index.10 The Balaban index J = J (G) of G is defined as: Table 1-A: Topological Indices and Biological (Inhibitory) Activity of NMDA Inhibitors (Training set). (3) where b is the number of bonds in G, is the cyclomatic number of G and d;and dk (i or j = 1,2,3....N the number of vertices in G) are the distance sums. Balaban Index has been successfully used in the various QSAR and QSPR studies.59,60 For understanding the quantitative structure-activity relationships, statistical analysis using uni- as well as multi-variate correlations were performed using multiple linear regression (MLR) and genetic function approximation (GFA) techniques and the results were then compared. First, a correlation matrix was derived, and then regression parameters were obtained. The results were summarized for comparison. In the case of GFA analysis linear, spline, quadratic, offset-quadratic and quadratic-spline terms were used, with a population size of 100 and number of generations as 10000. The value of add-new term was kept at 25, keeping all the other values as default with the initial length of equation at 4. 3. Results and Discussion The structural descriptors (namely W, 1%R, and J) for the NMDA inhibitors (training set) are given in Table 1-A. It also records their biological inhibitory activities, expressed as logIC50. Tablel-B reports the biological activity and the graph theoretical indices of the test set. No. COMPOUND logIC5o W J % 01 3.037 761.0 2.0674 9.5754 02 3.182 881.0 2.0394 9.9692 03 2.980 881.0 2.0424 9.9692 04 D¿C° 2.236 658.0 2.1633 9.1647 05 2.547 559.0 2.1538 8.6647 06 -càT 2.624 908.0 2.0693 10.0966 07 jcà^ 2.592 773.0 2.1359 9.5586 08 xà? 2.818 773.0 2.1244 9.5586 09 2.310 882.0 2.1160 10.0966 10 0.301 1699.0 1.7016 12.6142 11 1.083 1790.0 1.6286 12.6142 12 1.086 1956.0 1.6115 13.1140 13 J^xo 0.290 2036.0 1.7484 13.5629 14 0.602 1699.0 1.7168 12.6142 15 2.682 657.0 2.1308 9.0586 16 2.873 559.0 2.1472 8.6647 17 0.556 1842.0 1.7592 13.0417 18 ^ocr- 0.653 2160.0 1.6523 13.5460 No. COMPOUND logIC50 W J % 19 0.892 1916.0 1.6780 13.0080 20 0.982 1956.0 1.6181 13.1142 21 0.903 2080.0 1.6988 13.5629 22 jcáP^ 0.949 1505.0 1.7231 12.6142 23 0.556 3820.0 1.4348 16.0460 24 .xaScP""^ 1.037 1357.0 1.9716 11.4524 25 0.342 2432.0 1.6148 14.0460 26 .có^ 0.380 2160.0 1.6539 13.5460 27 0.954 4071.0 1.2735 16.5637 28 „jeófV N 1.879 1006.0 2.1265 10.4693 29 jOÓ^O 1.068 2120.0 1.6419 13.5249 30 1.009 1997.0 1.6255 13.6142 31 0.778 1997.0 1.5811 13.6142 32 0.519 1738.0 1.6308 12.6142 33 1.806 403.0 2.4711 7.4861 34 jócíx^ 0.602 1504.0 1.7732 11.9356 35 XCC? 2.751 674.0 1.9440 9.1479 36 .JCCC 2.004 423.0 2.2261 7.6134 No. COMPOUND logIC50 W J 1XR 37 xA. 2.004 226.0 2.4656 6.1647 38 xfx, 2.004 269.0 2.5180 6.4880 39 0.260 1640.0 1.5886 11.9524 40 0.422 1900.0 1.5800 12.4524 41 0.418 2186.0 1.5065 12.9524 42 0.852 1622.0 1.6791 11.9692 43 0.467 1658.0 1.6540 11.9524 44 1.439 1456.0 1.6747 11.5586 45 v> -0.367 2051.0 1.4227 13.0249 46 N, -0.569 2132.0 1.6572 12.9904 47 c¿c 2.004 488.0 2.4093 8.1471 48 XÓC 2.004 572.0 2.4331 8.5409 49 cfic 2.004 566.0 2.4692 8.5577 50 xéc 1.021 1122.0 2.5847 10.7730 51 2.004 400.0 2.5770 7.5029 52 2.004 1242.0 1.8045 11.0586 53 OH O .QX" M 2.004 400.0 2.5693 7.5029 No. COMPOUND logIC50 W J 1XR 54 flj H\) 1.041 1456.0 1.6852 11.5585 55 . J.......o 0.602 1504.0 1.8140 11.9356 Table 1-B: Structure and Experimental logIC50 values of NMDA Inhibitors (Test Set). No. COMPOUND logIC50 W J 1XR M ¿f " 1.585 1930 1.7385 11.9356 2.004 1456 1.6734 11.5586 ■ 3.348 1261 1.8248 11.5586 1.561 1568 1.7981 11.9524 05 1.535 1956 1.7249 13.1142 3.477 1275 1.6921 11.0585 1.446 2509 1.534 14.5974 08 p> 1.630 2574 1.675 14.3294 09 . . 1.513 2078 1.6368 13.4356 10 ^ ^ ^2.913 644 2.171 9.0754 Table 2 summarizes the comparison of uni- and multivariate analysis using GFA and MLR methods. The bi-variate results have not shown any significant improvement in the correlation coefficient and thus are excluded from the table. Table 2: Regression parameters, Quality of correlation of logIC50) with the Structural Descriptors for NMDA Inhibitors. Index Correlation Parameter MLR GFA W R2 0.537 0.891 Q2 0.459 0.887 F-ratio 61.593 154.289 1XR R2 0.565 0.893 Q2 0.527 0.880 F-ratio 68.722 216.393 J R2 0.461 0.818 Q2 0.419 0.796 F-ratio 45.271 117.103 W,1XR,J R2 0.566 0.932 Q2 0.429 0.923 F-ratio 22.197 233.431 The logIC50 for the NMDA inhibitors were estimated using the best correlation obtained from both MLR as well as GFA techniques, and such estimated logIC50 values are recorded in Table- 3 for both MLR and GFA. The residuals demonstrate the quality of correlations, i.e. difference between the observed and estimated logIC50 values and are given in Table-3. Table-4 presents the results obtained for the test set. Also, it records the regression parameters estimated for the test set. The correlation parameters obtained also indicate that GFA performs better as compared to MLR. In the training set, the prediction power of GFA was very high and also it performed better in estimating the activity values for the test set. As seen in equation 2, the spline terms used in the case of GFA are truncated power splines and are denoted by angle brackets (<, >). Table 3: Observed and Estimated logIC50 values of NMDA Inhibitors (training set) from the regression equations (1) (MLR) and (2) (GFA) (MLR) logIC50= 8.43042 - 0.00025036W - 1.24785J - 0.377459(1Xr) (1) (GFA) logIC50= 0.668898 + 0.011932 <1505 - W> + 6.905072 - 0.010232<1250 - - W> - 5.69173 (2) Linear GFA No. logIC50 logIC50 Resd. logIC50 Resd. (Obs5 (Pred) (Pred5)0 01 3.04 1.89 1.15 2.78 0.26 02 3.18 1.78 1.41 2.85 0.33 03 2.98 1.78 1.20 2.85 0.13 Linear GFA No. logIC50 logIC50 Resd. logIC50 Resd. (Obs) (Pred) (Pred) 04 2.24 2.00 0.24 2.60 -0.36 05 2.55 2.14 0.41 2.57 -0.03 06 2.62 1.74 0.88 2.64 -0.02 07 2.59 1.89 0.71 2.67 -0.08 08 2.82 1.89 0.93 2.69 0.13 09 2.31 1.74 0.57 2.57 -0.26 10 0.30 1.03 -0.73 0.66 -0.36 11 1.08 1.02 0.06 0.66 0.42 12 1.09 0.88 0.21 0.66 0.42 13 0.29 0.74 -0.45 0.66 -0.37 14 0.60 1.03 -0.43 0.66 -0.06 15 2.68 2.03 0.66 2.64 0.04 16 2.87 2.14 0.74 2.59 0.29 17 0.56 0.90 -0.34 0.66 -0.11 18 0.65 0.74 -0.08 0.66 -0.01 19 0.89 0.90 -0.01 0.66 0.23 20 0.98 0.88 0.11 0.66 0.32 21 0.80 0.74 0.06 0.66 0.14 22 0.95 1.18 -0.23 0.66 0.29 23 0.56 -0.12 0.67 0.66 -0.11 24 1.04 1.35 -0.31 1.03 0.01 25 0.34 0.57 -0.23 0.66 -0.32 26 0.38 0.74 -0.36 0.66 -0.28 27 0.95 -0.27 1.22 0.66 0.29 28 1.88 1.63 0.25 2.07 -0.19 29 1.07 0.75 0.32 0.66 0.40 30 1.01 0.75 0.26 0.66 0.35 31 0.78 0.75 0.03 0.66 0.11 32 0.52 1.03 -0.51 0.66 -0.14 33 1.81 2.42 -0.62 1.99 -0.18 34 0.60 1.22 -0.62 0.66 -0.06 35 2.75 2.02 0.73 2.94 -0.19 36 2.00 2.41 -0.40 2.38 -0.38 37 2.00 2.77 -0.77 1.90 0.11 38 2.00 2.68 -0.68 1.84 0.16 39 0.26 1.21 -0.95 0.66 -0.40 40 0.42 1.05 -0.63 0.66 -0.24 41 0.42 0.89 -0.47 0.66 -0.25 42 0.85 1.20 -0.35 0.66 0.19 43 0.47 1.20 -0.74 0.66 -0.20 44 1.44 1.33 0.11 1.15 0.29 45 0.37 0.90 -0.53 0.66 -0.30 46 0.57 0.88 -0.31 0.66 -0.09 47 2.00 2.25 -0.25 2.14 -0.13 48 2.00 2.14 -0.14 2.13 -0.13 49 2.00 2.14 -0.13 2.08 -0.07 50 1.02 1.50 -0.48 0.96 0.06 51 2.00 2.41 -0.41 1.83 0.18 52 2.00 1.47 0.53 1.80 0.20 53 2.00 2.41 -0.41 1.84 0.17 54 1.04 1.33 -0.29 1.15 -0.11 55 0.60 1.22 -0.62 0.65 -0.05 Table 4: Observed and Estimated log(1/C) values of NMDA Inhibitors (Test Set) from the regression equations EQ1(MLR) and EQ2 (GFA) Linear GFA No. logIC50 logIC50 Resid- logIC50 Resid- (Obs) (Calc) uals (Calc) uals 01 1.59 1.91 -0.32 1.57 0.02 02 2.00 2.40 -0.40 1.98 0.03 03 3.35 2.42 0.93 3.39 -0.05 04 1.56 2.25 -0.69 1.47 0.09 05 1.54 1.83 -0.29 1.57 -0.03 06 3.48 2.58 0.89 3.48 0.00 07 1.45 1.29 0.15 1.57 -0.12 08 1.63 1.35 0.28 1.57 0.06 09 1.51 1.72 -0.21 1.57 -0.06 10 2.91 3.26 -0.34 2.84 0.07 Linear GFA R2 0.544 0.993 Q2 0.318 0.990 4. Conclusions The present 2D-QSAR study related to NMDA inhibitors leads us to make the following conclusions: (i) Of the two methods of correlations, namely MLR and GFA, GFA proved to be better in its predicting ability. (ii) In MLR as well as GFA case of uni-variate analysis, Randic index (1%R) showed the best correlation, even though its predicting power was comparatively very poor in MLR. (iii) The best correlation was obtained with the multi-variate correlation, i.e. all the indices combined together, where the prediction power was very high for GFA (R2 = 0.932 and Q2 = 0.923) but was comparatively lower in the case of MLR (R2 = 0.566, Q2 = 0.429). (iv) The results of the test set support the findings. On the basis of the results obtained from these studies, it is evident that GFA should be used in preference to MLR for performing statistical analysis which will help in predicting the properties of novel molecules and thus novel molecules could be designed possessing better biological/inhibitory activity. 5. Acknowledgement The authors wish to acknowledge Director, S.G.S.I.T.S, Indore, for providing necessary computational facilities, to complete a part of this work. 6. References 1. V. Venkatraman, A. R. Dalby, Z. R. Yang, J. Chem. Inf. Comput. Sci., 2004, 44, 1686-1692. 2. J. S. Duca, A. J. Hopfinger, J. Chem. Inf. Comput. Sci., 2001, 41, 1367-1387. 3. A. T. Balaban, Fundam. Inform, 2005, 64(1-4), 1-16. 4. M. Randic and A. T. Balaban, J. Chem. Inf. Model., 2006, 46(1), 57 - 64. 5. V. G. Tsirelson, E. V. Bartashevich, A. I. Stash, V. A. Potemkin, Acta Cryst., 2007, B63, 142-150. 6. W. Zheng, A. Tropsha, J. Chem. Inf. Comput. Sci., 2000, 40, 185-194. 7. A. T. Balaban, Chemical Applications of Graph Theory: Academic Press, London, 1976, 83-110. 8. H. González-Díaz, L. Saiz-Urra, R. Molina, L. Santana, and E. Uriarte, J. of Proteome Res., 2007, 6, 904-908. 9. H. González-Díaz, R. Ramos De Armas, R. Molina, Bioinformatics, 2003,19, 2079-2087. 10. H. González-Díaz, M. C. Monteagudo, D. Viña, L. Santana, E. Uriarte and Eric De Clercq, Bioorg. and Med. Chem. Lett., 2005,15, 1651-1657. 11. T. Ivanciuc, O. Ivanciuc, and D. J. Klein, J. Chem. Inf. Model., 2005, 45(4), 870-879. 12. L. B. Kier, L. H. Hall, Molecular Connectivity in Chemistry and Drug Research, Academic Press: New York, 1976,60-110. 13. M. Randic, J. Zupan, J. Chem. Inf. Comput. Sci., 2001, 41(3), 550-560. 14. N. Trinajstic, Chemical Graph Theory, CRC Press: Boca Raton, FL, Vol. 2, 1983, 5-52. 15. I. Gutman, Z. Tomovif, J. Chem. Inf. Comput. Sci., 2000, 40(6), 1333-1336. 16. H. Wiener, J. Am. Chem. Soc., 1947, 69, 17-20. 17. M. Randic, J. Am. Chem. Soc., 1975,97, 6609-6615. 18. S. Bereg , H. Wang, Discrete App. Mathematics, 2007, 155(4), 457-467. 19. C. L. Thompson, D. L. Drewery, H. D. Atkins, F. A. Stephenson, P. L. Chazot, Neurosci. Lett., 2000, 283(2), 85-88. 20. T. W. Stone, Pharmacol. Reviews, 1993, 45, 309-379. 21. J. C. Watkins, D. E. Jane, British J. of Pharmacol., 2006, 147, S100-S108. 22. J. W. Olney, Annu. Rev. Pharmacol. Toxicol., 1990, 30, 47-71. 23. K. W. Muir, Current Opinion in Pharmacol., 2005, 6 (1), 53-60. 24. D. M. Robinson, G. M. Keating, Drugs, 2006, 66 (11), 1515-1534. 25. J. A. Kemp, P. D. Leeson, Pharmacol Sci., 1993,14, 20-25. 26. I. I. Abramets, I. M. Samoilovich and N. A. Kharin, Neurophysiology, 1996, 28, 163-172. 27. D. T. Manallack, M. G. Wong, R. D. O'Shea, P. M. Beart, Mol. Neuropharmacol., 1990, 1, 7. 28. R. D. Allan, J. R. Hanrahan, T. W. Hambly, G. A. R. Johnston, K. N. Mewett, A. D. Mitrowic, J. Med. Chem, 1990, 33, 2905-2915. 29. H. J Olverman, A. W. Jones, K. N. Mewett, J. C. Watkins, Neuroscience, 1988,26, 17-31. 30. J. C. Brown III, H. W. Tse, D. A. Skifter, J. M. Christie, V. J. Andaloro, M. C. Kemp, J. C. Watkins, D. E. Jane, D. T. Monaghan, J. Neurochem, 1998, 71, 1464-1470. 31. J. P. Pin, R. Duvoisin, Neuropharmacology, 1995,34, 1-26. 32. A. Auerbach and Y. Zhou, The Journal of Neuroscience, 2005,25(35), 7914-7923. 33. W. F. van Gunsteren, H. J. C. Berendsen, Angew. Chem. Int. Ed. Eng., 1990, 29, 992-1023. 34. S. Boresch, M. Karplus, J. Mol. Biol 1995, 254, 801-807. 35. T. Hansson, C. Oostenbrink, W. F. van Gunsteren, Curr. Opin. Struct. Biol. 2002,12, 190-196. 36. U. Bren, V. Martinek, J. Florian, J. Phys. Chem. B, 2006, 110, 12782-12788. 37. M. Bren, J. Florian, J. Mavri, U. Bren, Theoretica Chimica Acta, 2007,117(4), 535-540. 38. J. Florian, A. Warshel, J. Phys. Chem. B, 1997, 101 (28), 5583 -5595. 39. J. Florian, M. F. Goodman, A. Warshel, J. Phys. Chem. B, 2000,104, 10092-10099. 40. J. Davies, J. C. Watkins, Brain Res., 1982, 235, 378-386. 41. T. J. Biscoe, R. H. Evans, A. A. Francis, M. R. Martin, J. C. Watkins, J. Davies, Br J Pharmacol., 1982, 75(1), 65-75. 42. T. Marti, D. Benke, S. Mertens, R. Heckendorn, M. Pozza, H. Allgeier, C. Angst, D. Laurie, P. Seeburg, H. Mohler, Eur J Pharmacol., 1990,182 (1), 91-100. 43. W. Müller, P. Kipfer, D. A. Lowe, S. Urwyler, Neurophar-macology, 1996, 35, 643-654. 44. M. Kessler, M. Baudry, T. Terranoui, G. Lynch, Soc Neurosci. Abstr, 1987, 13, 760. 45. F. Gardoni, M. Di Luca, European J. of Pharmacol., 2006, 545 (1): 2-10. 46. J. A. Kemp, A. C. Foste, P. D Leeson, T. Priestley, R. Tridgett, L. L. Iversen, G. N. Woodruff, Proc. Natl. Acad. Sci. USA, 1988, 85, 6547-6550. 47. P. D. Leeson, R. Baker, R. W. Carling, N. R. Curtis, K. W. Moore, B. J. Williams, A. C. Foster, A. E. Donald, J. A. Kemp, G. R. Marshall, J. Med. Chem., 1991,34, 1243-1251. 48. B. M. Baron, B. L. Harrison, F. P. Miller, I. A. McDonald, F. G. Salituro, C. J. Schmidt, S. M. Sorensen, H. S. White, M. G. Palfreyman, Mol. Pharmacol., 1990,38, 554-561. 49. F. Moroni, M. Alesiani, A. Galli, A. Mori, A. Pecorari, V. Carla, G. Cherici, R. Pellicciari, Eur. J. Pharmacol, 1991, 199, 227-232. 50. P. D. Leeson, L. L. Iversen, J. Med. Chem, 1994, 37, 4053-4067. 51. S. J. Patankar, P. C. Jurs, J. Chem. Inf. Comput. Sci. 2002,42, 1053-1068. 52. SYBYL Molecular Modelling Software, version 6. 9, Tripos Associates Inc. St. Louis, MO, 2002. 53. Cerius2® version 4. 6, Accelrys Inc, San Diego, CA 2001. 54. L. I. Stiel, G. Thodos, Am. Ins. Chem. Eng. J., 1962, 8, 527-529. 55. D. H. Rouvray, B. C. Crafford, South Africa J. of Sci, 1976, 72, 47-51. 56. D. Papazova, M. Dimov, D. Bonchev, J. of Chrom., 1980, 188, 297. 57. M. Medic-Saric, D. Maysinger, M. Morvin, Acta. Pharma. 59. A. T. Balaban, D. Ciubotariu, M. Medeleanu, J. Chem. Inf. Comput. Sci., 1991,31, 517. 60. A. T. Balaban, Chem. Phys. Lett., 1982, 89, 399-404. Jugosl., 1983,33, 199. 58. L. B. Kier, L. H. Hall and J. W. Frazer, J. Chem. Inf. Comput. Sci., 1993,33, 143-147. Povzetek Opravljena je bila primerjalna raziskava uporabe dvodimenzionalnega modeliranja povezav med kemijsko strukturo in biološko aktivnostjo (2D-QSAR) na primeru N-metil-D-aspartatnih (NMDA) inhibitorjev. V študiji smo primerjali modeliranje z uporabo genetske funkcijske aproksimacije (GFA) in multiple linearne regresije (MLR). Za opis kemijske struktur smo uporabili topološke povezovalne indekse in indekse razdalj (Wienerjev, Balabanov, in Randicev indeks). Z izdelanimi modeli smo napovedovali inhibicijske sposobnosti testnega podatkovnega seta. GFA metoda generira boljše 2D QSAR modele tako pri modeliranju ob uporabi ene kot tudi vecih spremenljivk. V študiji smo primerjali tudi mode-lirne sposobnosti posameznih indeksov. V vseh primerih (Wienerjev, Balabanov, Randicev indeks) smo dobili dobre ko-relacijske parametre (R2 > 0.80, Q2 > 0.79) ob uporabi GFA tehnike, medtem ko je MLR tehnika dala slabše korelacije (R2 < 0.60, Q2 < 0.55). Med tremi indeksi je najboljši 2D-QSAR model za napovedovanje aktvnosti NMDA inhibitorjev dal Randicev indeks (R2 = 0.89, Q2 = 0.88, F-ratio = 216).